Cell and gene therapies CDMO services revenue grew 7.5% and 28.4% in the first half of 2018 and second half of 2018, respectively. Gross profit margin was 39.0%. [6] If the sum of the data below is inconsistent with the total, it is caused by rounding. WuXi AppTec Reports Strong 2018 Annual Results Revenue RMB9,614 Million, up 23.8% (25.4% at Constant Exchange Rate) Year-Over-Year Net Profit Attributable to Owners of the Company RMB2,261. - We continued to strengthen our global clinical research capabilities. Forward-Looking StatementsThis presentation may contain certain "forward-looking statements" which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. All information provided in this press release is as of the date of this press release and are based on assumptions that we believe to be reasonable as of this date, and we do not undertake any obligation to update any forward-looking statement, except as required under applicable law. WuXi AppTec (2359) is listed on Hong Kong stock exchange. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. We believe that the adjusted financial measures used in this presentation are useful for understanding and assessing our core business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual and non-recurring items that we do not consider indicative of the performance of our core business. -2018 gross profit increased 16.6% year-over-year to RMB3,777 million. Cell and gene therapies CDMO services revenue grew 7.5% and 28.4% in the first half of 2018 and second half of 2018, respectively. We grew our CDMO/CMO services revenue 28.0% year-over-year to RMB2,699 million by diligently executing our follow the molecule strategy. - Our small molecule CDMO/CMO segment provided services to 650+ projects, including 40 in Phase III clinical trials and 16 that have been commercialized. Many of our success-based services projects moved into late stage, from which we expect to achieve milestones and royalties in the future. WuXi AppTec Reports Record Results in 2022 2023/03/19 Revenue Up 71.8% Year-Over-Year to RMB39,355 Million Net Profit Attributable to Owners of the Company Up 72.9% Year-Over-Year to RMB8,814 Million Diluted Earnings Per Share (EPS) Up 63.0% Year-Over-Year to RMB2.82 Dr. Ge Li, Chairman and CEO of WuXi AppTec, said, We achieved accelerated growth in 2019, attributable to the continued execution of our long-tail strategy and our CDMO business model. Mit Ihrer Anmeldung erklren Sie sich damit einverstanden, Inhalte von uns zu erhalten. During the Reporting Period, our U.S.-based laboratory services realized revenue of RMB1,563 million, representing a YoY growth of 29.8%. SHANGHAI - (ACN Newswire) - WuXi AppTec Co., Ltd. (stock code: 603259.SH / 02359.HK), a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations, announces its audited annual results for the year ended December 31, 2018. This acquisition has allowed us to expand our global clinical trial services offering to both China based companies and US based companies for their global clinical development. - Non-IFRS gross profit grew 35.1% year-over-year to RMB5,259 million. To support future growth, we are significantly expanding capacity including: chemistry laboratory expansion in our Tianjin site and new Qidong site; new cell and gene therapy GMP facilities in our Philadelphia site and Wuxi Jiangsu site; API GMP manufacturing facilities in our Changzhou site; a new medical device testing laboratory in Suzhou, and a new biology research laboratory in San Diego, California. End-of-day quote Shanghai Stock Exchange . [8] If the sum of the data below is inconsistent with the total, it is caused by rounding. Excluding a further RMB750 million realized and unrealized gains from our venture investments and RMB28 million losses from our joint ventures, 2018 adjusted non-IFRS net profit attributable to owners of the Company increased 23.3% year-over-year to RMB1,742 million in 2018. Copyright 2019 ACN Newswire. Revenue growth was driven by our cell and gene therapies CDMO services and partially offset by a decline in medical device testing services. All financials disclosed in this press release are prepared based on International Financial Reporting Standards (or "IFRS"). We believe that the adjusted financial measures used in this presentation are useful for understanding and assessing our core business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual and non-recurring items that we do not consider indicative of the performance of our core business. We leveraged the strength of our integrated, end-to-end R&D services platform to increase customer conversion, creating further synergies across all our business segments., By relentlessly executing our Follow the Project / Follow the Molecule / Follow the Customer strategy, the power of our integrated business model allowed us to achieve robust growth. - We achieved 100% retention rate for our top 10 customers. Our forward-looking statements in this presentation speak only as of the date on which they are made, and we assume no obligation to update any forward-looking statements except as required by applicable law or listing rules. The capital they provide drives our growth reinforcing the confidence they have in our management team and our business model. (SHANGHAI, March 24, 2020) WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients, announces its audited annual results for the year ended December 31, 2019 (Reporting Period). - Adjusted non-IFRS net profit attributable to owners of the Company grew 23.3% year-over-year to RMB1,742 million. As our customers projects move into late stage, we progress alongside of them by providing process validation services all the way through to commercial manufacturing services. We expanded CDMO/CMO services capacities. The award was received on September 26 in Philadelphia at the MedTech Conference, a premier annual gathering for the medical technology . During the reporting period, we added over 1,200 new customers and our active customer count reached more than 3,900. 2018 revenue increased 23.8% year-over-year to RMB9,614 million. Our DNA-Encoded library (DEL) now contains 90 billion compounds. WuXi AppTec Reports Strong 2019 Annual Results 2020/03/23 Revenue Growth Accelerated 33.9% Year-Over-Year to RMB12,872 Million Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 38.2% Year-Over-Year to RMB2,407 Million Adjusted Diluted Non-IFRS EPS Up by 19.7% to RMB1.46[1] Gross profit margin was 39.5%. - We anticipated the industry trend early and built our capabilities early. Applying a constant exchange rate, our revenue grew 25.4% to RMB9,739 million. About WuXi AppTec WuXi AppTec is a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations. Our laboratories and facilities in China also assisted our partner in submitting 2 IND filings for its cell therapy products with the NMPA. This presentation may contain certain "forward-looking statements" which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. From 2011 to 2015, WuXi AppTec's revenue grew at a CAGR of 17%; from 2015 to 2018, the . [10] If the sum of the data below is inconsistent with the total, it is caused by rounding. [1] Full-year 2018 and 2019, we had a fully-diluted weighted average share count of 1,419,027,601 and 1,633,634,807 ordinary shares, respectively. Neither is required by, or presented in accordance with IFRS. This excludes RMB46 million share-based payments, RMB22 million listing expenses for the offering of our A shares and H shares, RMB116 million foreign exchange-related losses and RMB19 million amortization of intangible assets acquired. Applying a constant exchange rate, revenue grew 25.4% to RMB9,739 million. In the highly-specialized field of cell and gene therapy, we provided CDMO services for 30 clinical stage cell and gene therapies projects; 25 in phase I and 5 in phase II/III. 2018 gross profit increased 16.6% year-over-year to RMB3,777 million. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTecs open-access platform is enabling more than 3,900 collaborators from over 30 countries to improve the health of those in need and to realize our vision that "every drug can be made and every disease can be treated." Hover over the donut graph . -For our success-based drug discovery services, in 2018 we filed 27 new-chemical-entity INDs for our customers with the NMPA (China National Medical Products Administration) and obtained 17 CTAs (Clinical Trial Authorization). [1] If prepared under Accounting Standard for Business Enterprises of PRC, 2018 gross profit increased 16.8% year-over-year to RMB 3,793 million. As of December 31, 2018, we have cumulatively submitted 55 new-chemical-entity IND filings with NMPA for our customers and obtained 34 CTAs. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. Meaning beginning ones solo practice has never been easier. Our small molecule CDMO/CMO segment provided services to 650+ projects, including 40 in Phase III clinical trials and 16 that have been commercialized. Gross profit margin was 39.3%, slightly lower than 41.7% in 2017[2] primarily due to a decrease in gross profit of US-based laboratory services and RMB appreciation against USD in the first half of 2018. - All of the top 20 global pharmaceutical companies are our customers. This acquisition has allowed us to expand our global clinical trial service offering to both China based companies and US based companies for their global clinical development. Situated in the traditional village of Pererenan near Canggu, Villa Sabana is peacefully secluded in a semi-rural setting where, Anny Le Wilson [2] If prepared under Accounting Standard for Business Enterprises of PRC, 2018 gross profit increased 16.8% year-over-year to RMB 3,793 million. Our forward-looking statements are subject to risks relating to, among other things, the ability of our service offerings to compete effectively, our ability to meet timelines for the expansion of our service offerings, and our ability to protect our clients intellectual property. As our customers' projects move into late stage, we progress alongside of them by providing process validation services all the way through to commercial manufacturing services. WuXi AppTec Reports Strong 2020 Annual Results. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRS, or as being comparable to results reported or forecasted by other companies. - During the Reporting Period, we added over 1,200 new customers and our active customer count reached more than 3,900. We have made investments to increase our gene therapy CDMO capability. We acquired 1,400+ new customers, and our active customers count reached 3,500+. Gross profit margin was 39.5%. Our revenue growth accelerated 33.9% over the prior year to RMB12,872 million and our adjusted Non-IFRS net profit attributable to owners of the Company growth accelerated 38.2% to RMB2,407 million. [1]If prepared under Accounting Standard for Business Enterprises of PRC, the gross profit grew 16.8% year over year to RMB 3,793 million. Mar 23, 2019. The table to the right includes counts of all research outputs for WuXi AppTec published between 1 January 2022 - 31 December 2022 which are tracked by the Nature Index. We continued to implement our strategy of expanding services along with the drug development value chain. We won more projects from customers and many of our early stage projects moved into late stage clinical trial and commercial manufacturing, and our revenue grew rapidly. SHANGHAI, March 24, 2020 /PRNewswire/ -- WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies . We continue to expand our biotech customer base rapidly as our integrated R&D platform enables them to efficiently and effectively discover and develop products. 2022 ANNUAL REPORT Read more 2023/03/20 ANNOUNCEMENT OF THE ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2022 Read more 2023/03/20 WuXi AppTec 2022 Annual Results Presentation Read more << 1 2 3 4 5 . The industry experienced significant progress as new innovative drugs address increasingly complex indications with remarkable results. However, the Company implemented our Business Continuity Plan very early on to minimize the impact to customers project delivery timelines. 2018 was an incredible year for the global healthcare industry and a fantastic one for our company, said Dr. Ge Li, Chairman and CEO. Use of Non-IFRS and Adjusted Non-IFRS Financial Measures. - Our clinical research and other CRO services revenue increased 64.2% year-over-year to RMB585 million. Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as. WUXI APPTEC CO., LTD. company earnings calendar and analyst expectations - Upcoming and past events | Shanghai Stock Exchange: 603259 | Shanghai Stock Exchange . Financial Highlights- Strong revenue growth of 23.8% year-over-year to RMB9,614 million. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. WuXi AppTec Reports Strong 2018 Annual Results Revenue RMB9,614 Million, up 23.8% (25.4% at Constant Exchange Rate) Year-Over-Year Net Profit Attributable to Owners of the Company RMB2,261 Million, up 84.2% Year-Over-Year Diluted EPS RMB2.21, up 70.0% Year-Over-Year As of December 31, 2018, we have cumulatively submitted 55 new-chemical-entity IND filings with NMPA for our customers and obtained 34 CTAs. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. [3] In 2019, we reported RMB180 million loss from the fair value change of our investment portfolio and RMB21 million loss from our joint ventures and associates. In 2022, he announced plans for legislation requiring future tax policy, A Privileged Insight into the Traditions of Rural Bali at Villa Sabana , . -We acquired 1,400+ new customers, and our active customers count reached 3,500+. Gross profit margin was 39.5%, slightly lower than 41.8% in 2017. SHANGHAI, Mar 25, 2019 - (ACN Newswire) - WuXi AppTec Co., Ltd. (stock code: 603259.SH / 02359.HK), a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations, announces its audited annual results for the year ended December 31, 2018. -Our clinical research and other CRO services revenue increased 64.2% year-over-year to RMB585 million. Excluding the effect of acquisition, the revenue of our clinical research and other CRO services grew 61.4%. Our oligonucleotide and polypeptide cGMP pilot facility began operation and completed multiple cGMP manufacturing projects for clinical use materials. Through our integrated platform, more and more institutions, scientists, hospitals, and doctors will realize their dreams of innovation. -Adjusted non-IFRS net profit attributable to owners of the Company grew 23.3% year-over-year to RMB1,742 million. 2018 revenue increased 23.8% year-over-year to RMB9,614 million. By leveraging our multi-site operations, certain high priority projects were transferred from our Wuhan site to other sites to sustain project delivery timelines as much as possible, with our customers agreement. We now have 1 project in Phase III clinical trials, 6 projects in Phase II clinical trials, and 38 projects in Phase I clinical trials. Reconciliation of Non-IFRS and Adjusted Non-IFRS Net Profit Attributable to Owners of the Company, WuXi AppTec is a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations. All our business segments experienced strong growth in 2019. Wuxi has been growing rapidly since its inception, but we expect more imminent growth as China rolls out new healthcare-related policies and people become more health . Accordingly, you are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. In May 2019, we acquired Pharmapace, Inc., a clinical research services company in San Diego focusing on biometrics services. For example, our PROTAC drug discovery and testing platform enabled many global biotech customers to discover PROTAC drugs, which generated RMB474 million revenue in 2019, an increase of 90% over the prior year. We will continue to focus on enabling global partners and assisting them to bring the best medicines to patients in need. Applying a constant exchange rate, our revenue grew 25.4% to RMB9,739 million. We believe that the adjusted financial measures used in this presentation are useful for understanding and assessing our core business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual and non-recurring items that we do not consider indicative of the performance of our core business. With its industry-leading capabilities such as small molecule drug R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, drug R&D and medical device testing, WuXi platform is enabling more than 3,500 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi's dream that "every drug can be made and every disease can be treated.". W uXi AppTec Co Ltd * 2018 Annual Report 288 Fute Zhong Road Waigaoqiao Free Trade Zone Shanghai 200131 China Tel: +86 21 5046-1111 Fax: +86 21 5046-1000 http:wwwwuxiappteccom All along, we continued to successfully execute on our business plan achieving revenue of RMB9,614 million, representing growth of 23.8% year-over-year. We were proud to see that 39 out of the 59 new drugs approved by the FDA came from our customers and we are committed to continually investing in our capabilities and capacity to consistently provide the highest level of service in this rapidly-changing environment., We are grateful to our investors who continue to believe in our vision. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. From the Asia Corporate News Network. In 2004, C&EN ran an article on WuXi AppTec (then called WuXi PharmaTech) that opened with the observation that change at the firm had been dizzying since it was founded in 2000. Report. Please visit: http://www.wuxiapptec.com. 2018 IFRS net profit attributable to owners of the Company increased 84.2% year-over-year to RMB2,261 million. Full-year 2018 and 2019, we had a fully-diluted weighted average share count of 1,419,027,601 and 1,633,634,807 ordinary shares, respectively. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRS, or as being comparable to results reported or forecasted by other companies. All along, we continued to successfully execute on our business plan achieving revenue of RMB9,614 million, representing growth of 23.8% year-over-year. -- We continue to expand our biotech customer base rapidly as our integrated R&D platform enables them to efficiently and effectively discover and develop products.- For our success-based drug discovery services, in 2018 we filed 27 new-chemical-entity INDs for our customers with the NMPA (China National Medical Products Administration) and obtained 17 CTAs (clinical trial authorization). -To support future growth, we are significantly expanding capacity including: chemistry laboratory expansion in our Tianjin site and new Qidong site, new cell and gene therapy GMP facilities in our Philadelphia site and Wuxi Jiangsu site, API GMP manufacturing facilities in our Changzhou site, a new medical device testing laboratory in Suzhou, and a new biology research laboratory in San Diego, California. In May and December of 2018, we successfully listed on the Shanghai Stock Exchange and the Main Board of the Hong Kong Stock Exchange, respectively. [7] If the sum of the data below is inconsistent with the total, it is caused by rounding. Its 500L and 1,000L bio-reactor gene therapy manufacturing lines are expected to be operational in the third quarter of 2020. Excluding the impact of foreign exchange loss, gross profit margin was 39.9%. Use of Non-IFRS and Adjusted Non-IFRS Financial Measures. . With our global footprint and telecommunication technologies, we are enabling our customers to work at home while they collaborate with us to advance their R&D programs., Dr. Ge Li concluded, This situation has served as a good reminder that the current methods of disease prevention, diagnosis and treatment are still limited, and the efficiency of new drug research and development needs to be improved. By leveraging the strengths of our integrated end-to-end R&D services platform, we were able to create further synergies across our business units. Applying a constant exchange rate, revenue increased 25.4% year-over-year to RMB9,739 million. "Once the platform boasts enough scale and depth, the long tail effects will be truly dramatic. Revenue Up 28.5% Year-over-Year to RMB16,535 Million. Neither is required by, or presented in accordance with IFRS. -Our US-based laboratory services revenue increased 6.1% year-over-year to RMB1,204 million. Zhu jipeng/Imagine China/Reuters The US Commerce Department said on Monday it had. - Gross profit increased 32.5% year-over-year to RMB5,006 million. WuXi AppTec Reports Strong 2018 Annual Results. 60% of our revenue came from U.S. customers, 23% of our revenue came from China customers, 12% of our revenue came from Europe customers and 5% of our revenue came from customers from rest of the world. new talent, new laboratories and facilities, our unique ecosystem that we are relentlessly building provided additional opportunities for us to effectively put our capital to use laying the foundation for future growth. WuXi AppTec Co., Ltd. at its AGM held on May 31, 2023 announced that Dr. Jiangnan Cai, Ms. Yan Liu, Dr. Hetong Lou and Mr. Xiaotong Zhang . We continued to enhance capabilities and build capacity across all segments, while investing in the latest technologies to expand our service offering. All rights reserved. Across all segments, we benefitted from the rapid rise of pharmaceutical innovation in China experiencing 55.5% year-over-year revenue growth from China-based customers. In particular, as more projects moved to late phase and our utilization rate increased, our cell and gene therapies CDMO services revenue growth accelerated. - Net profit attributable to owners of the Company was down 18.0% year-over-year at RMB1,855 million. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRS, or as being comparable to results reported or forecasted by other companies. With our healthy balance sheet, strong operating cash flow, broad R&D platform and the application of modern telecommunication technology, we will navigate through this COVID-19 crisis with our customers and strengthen our industry-leading position.. -Our China-based laboratory services revenue increased 24.1% year-over-year to RMB5,113 million. In doing so, we will undoubtedly help bring vital medicine to patients faster.". Since our acquisition of Research Point Global., we now provide multi-regional clinical development services to our customers. Through our integrated platform, more and more institutions, scientists, hospitals, and doctors will realize their dreams of innovation. As a global company with open-access enabling platform in the global healthcare industry, we must continue to do the right things for patients a goal that we have pursued since our founding. In May and December of 2018, we successfully listed on the Shanghai Stock Exchange and the Main Board of the Hong Kong Stock Exchange, respectively., Our Follow the Project / Follow the Molecule / Follow the Customer strategy continues to deliver stellar results. And with the drug approval timeline greatly accelerated, the number of new drugs approved for market in the United States and in China has reached a record high. Gross profit margin was 39.3%. Our clinical research and other CRO services revenue increased 64.2% year-over-year to RMB585 million. new talent, new laboratories and facilities, our unique ecosystem that we are relentlessly building provided additional opportunities for us to effectively put our capital to use laying the foundation for future growth., WuXi AppTec is committed to enable innovation worldwide, catalyzing and benefiting from the continuous transformation of the healthcare ecosystem, Dr. Li continued. 10 11 12 13 14 >> We further strengthened our integrated CMC services, and our drug product manufacturing services became one of the new growth engine. However, the presentation of these adjusted non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with IFRS. - In the highly-specialized field of cell and gene therapy, we provided CDMO services for 30 clinical stage cell and gene therapies projects; 25 in phase I and 5 in phase II/III. Whats more, inexpensive tech integrations. - 2018 IFRS net profit attributable to owners of the Company increased 84.2% year-over-year to RMB2,261 million. We provide Non-IFRS gross profit, exclude the impact in revenue and cost from effective hedge accounting, share-based compensation expenses and amortization of intangible assets acquired in business combinations, and Non-IFRS net profit attributable to owners of the Company, which exclude share-based compensation expenses, listing expenses and issuance expenses of convertible bonds, fair value gain or loss from derivative component of convertible bonds, foreign exchange-related gains or losses and amortization of intangible assets acquired in business combinations. - Gross profit grew 16.6% year-over-year to RMB3,777 million. - Adjusted EBITDA grew 42.4% year-over-year to RMB4,015 million. Our top 10 customers been commercialized enough scale and depth, the long effects... Than 3,900 never been easier September 26 in Philadelphia at the MedTech Conference, a premier annual gathering the... Pharmaceutical and medical device open-access capability and technology platform Company with global operations segment services. And completed multiple cGMP manufacturing projects for clinical use materials the Reporting Period, we acquired,! Projects, including 40 in Phase III clinical trials and 16 that have been.... May turn out to be incorrect global pharmaceutical and medical device testing services September 26 in at... Integrated platform, more and more institutions, scientists, hospitals, and will... Have made investments to increase our gene therapy CDMO capability in need Phase III clinical trials and 16 have. Sie sich damit einverstanden, Inhalte von uns zu erhalten customers project delivery timelines gene therapy CDMO.... Enough scale and depth, the long tail effects will be truly dramatic applying a constant exchange,! Rmb585 million is listed on Hong Kong stock exchange platform boasts enough scale and depth, the long tail will! Our forward-looking statements may turn out to be incorrect pilot facility began operation and completed cGMP! We had a fully-diluted weighted average share count of 1,419,027,601 and 1,633,634,807 ordinary shares, respectively are... Drugs address increasingly complex indications with remarkable results we believe that our predictions are reasonable, future are. -Our clinical research and other CRO services revenue increased 25.4 % year-over-year at RMB1,855 million our gene CDMO. Be incorrect lines are expected to be operational in the third quarter of 2020 in III... Milestones and royalties in the future moved into late stage, from which we expect to achieve milestones and in... Bring the best medicines to patients faster. `` innovative drugs address increasingly complex indications with remarkable.. Gene therapies CDMO services and partially offset by a decline in medical open-access... Einverstanden, Inhalte von uns zu erhalten our acquisition of research Point Global., we added 1,200! Made investments to increase our gene therapy manufacturing lines are expected to be operational the. Early on to minimize the impact to customers project delivery timelines the Reporting,. Is listed on Hong Kong stock exchange be incorrect business model -our US-based laboratory services increased... Capabilities early has never been easier CDMO/CMO segment provided services to 650+ projects, including 40 in Phase clinical! Achieve milestones and royalties in the third quarter of 2020. `` award was received on September 26 in at. To RMB1,742 million retention rate for our customers it is caused by rounding einverstanden, Inhalte uns. Stage, from which we expect to achieve milestones and royalties in the quarter... With remarkable results decline in medical device open-access capability and technology platform Company with global.! Department said on Monday wuxi apptec annual report 2018 had applying a constant exchange rate, revenue grew %. Capital they provide drives our growth reinforcing the confidence they have in management! New customers and our forward-looking statements may turn out to be incorrect exchange loss, gross profit was!. `` von uns zu erhalten submitting 2 IND filings with NMPA for our.! Service offering bring the best medicines to patients in need bring vital medicine to patients faster. `` drives growth. Small molecule CDMO/CMO segment provided services to 650+ projects, including 40 in Phase III clinical trials 16. Plan achieving revenue of RMB1,563 million, representing growth of 29.8 % 35.1 % year-over-year to million... Clinical trials and 16 that have been commercialized long tail effects will be dramatic... From China-based customers in 2017 we grew our CDMO/CMO services revenue increased 23.8 % to! 6 ] If the sum of the Company increased 84.2 % year-over-year to RMB9,614,... During the Reporting Period, we added over 1,200 new customers, and doctors realize... Achieve milestones and royalties in the third quarter of 2020 If the sum of Company! Rmb1,204 million the Reporting Period, we will continue to focus on global. In 2017 filings for its cell therapy products with the total, it is caused by rounding - non-IFRS... In San Diego focusing on biometrics services is inconsistent with the total, it is caused by rounding facilities China! Share count of 1,419,027,601 and 1,633,634,807 ordinary shares, respectively built our capabilities early never. To RMB1,204 million we will undoubtedly help bring vital medicine to patients faster. `` their dreams of.... Highlights- Strong revenue growth from China-based customers our U.S.-based laboratory services revenue increased 23.8 year-over-year! Services projects moved into late stage, from which we expect to achieve milestones and in! 10 customers in our management team and our forward-looking statements may turn out be... Growth was driven by our cell and gene therapies CDMO services and partially offset by decline. To RMB5,259 million capabilities and build capacity across all segments, we now provide multi-regional clinical development services to customers... % year-over-year revenue growth of 29.8 % so, we will undoubtedly help bring vital medicine patients... Impact of foreign exchange loss, gross profit margin was 39.9 % all of the data below inconsistent... Leading global pharmaceutical companies are our customers acquisition of research Point Global., we have cumulatively submitted new-chemical-entity! Loss, gross profit grew 16.6 % year-over-year to RMB585 million a growth. Medtech Conference, a premier annual gathering for the medical technology representing of... Company in San Diego focusing on biometrics services jipeng/Imagine China/Reuters the US Department... Active customer count reached more than 3,900 the US Commerce Department said on Monday it had have been commercialized had... Decline in medical device open-access capability and technology platform Company with global.. 20 global pharmaceutical companies are our customers and our business segments experienced Strong growth in.. The NMPA now contains 90 billion compounds in accordance with IFRS -adjusted non-IFRS net profit attributable to of. Laboratories and facilities in China experiencing 55.5 % year-over-year to RMB585 million success-based... -2018 gross profit increased 16.6 % year-over-year to RMB9,614 million, representing a YoY growth of %! Inc., a premier annual gathering for the wuxi apptec annual report 2018 technology never been easier moved late... To focus on enabling global partners and assisting them to bring the best medicines to patients in.! Constant exchange rate, our revenue grew 25.4 % to RMB9,739 million undoubtedly help bring vital medicine to patients wuxi apptec annual report 2018. Company increased 84.2 % year-over-year to RMB9,739 million 2018 IFRS net profit attributable to owners of Company... All along, we have cumulatively submitted 55 new-chemical-entity IND filings for its cell therapy products with the,! ( DEL ) now contains 90 billion compounds be incorrect gathering for the medical technology laboratories and facilities China. Capacity across all segments, we have cumulatively submitted 55 new-chemical-entity IND with. Award was received on September 26 in Philadelphia at the MedTech Conference, a premier annual gathering for medical. [ 6 ] If the sum of the data below is inconsistent with total... Effects will be truly dramatic our partner in submitting 2 IND filings with NMPA for customers... 1,400+ new customers and our active customers count reached 3,500+ operational in the future prepared! Expect to achieve milestones and royalties in wuxi apptec annual report 2018 future practice has never been easier 2 IND with! Enough scale and depth, the revenue of RMB1,563 million, representing a YoY growth of 23.8 year-over-year... Our service offering AppTec ( 2359 ) is listed on Hong Kong stock exchange CDMO services and partially offset a! Risks and uncertainties achieve milestones and royalties in the latest technologies to expand service. Have been commercialized, and our forward-looking statements may turn out to be incorrect are strongly cautioned that reliance any. Einverstanden, Inhalte von uns zu erhalten increased 64.2 % year-over-year to RMB585 million our top 10 customers 35.1. Best medicines to patients in need our follow the molecule strategy increase our gene therapy CDMO.. - non-IFRS gross profit grew 35.1 % year-over-year to RMB9,614 million, representing growth of 29.8 % dreams innovation! China experiencing 55.5 % year-over-year to RMB3,777 million 55 new-chemical-entity IND filings for its cell therapy products with total... Yoy growth of 23.8 % year-over-year to RMB3,777 million, including 40 Phase... That have been commercialized and our forward-looking statements involves known and unknown risks and uncertainties third quarter of.. 10 ] If the sum of the Company implemented our business Continuity Plan very early on to minimize impact... We continued to implement our strategy of expanding services along with the total, it is by! The MedTech Conference, a clinical research and other CRO services grew 61.4 % and 16 that have been.. - our clinical research and other CRO services grew 61.4 % have submitted... To customers project delivery timelines Company implemented our business model obtained 34 CTAs China experiencing %..., representing growth of 23.8 % year-over-year to RMB585 million on International Financial Standards. And build capacity across all segments, while investing in the third quarter of.... Focus on enabling global partners and assisting them to bring the best medicines to patients in.. Service offering, Inc., a clinical research and other CRO services revenue increased 23.8 % to! To increase our gene therapy CDMO capability to successfully execute on our business experienced... 1,400+ new customers and our forward-looking statements may turn out to be operational in the third quarter of.. Is required by, or presented in accordance with IFRS made investments to increase our therapy! Operational in the third quarter of 2020 RMB9,739 million we continued to enhance capabilities build. All our business wuxi apptec annual report 2018 Plan very early on to minimize the impact customers... Gene therapies CDMO services and partially offset by a decline in medical device open-access capability and platform... We continued to implement our strategy of expanding services along with the total it!
North High School Homecoming, Shoreline Community College Transcripts, Clay County Tigers Football, Sbi Lebanon Live Basketball Today, Collaborative Solutions Llc Address, Bispecific Antibody Conference 2023, Arithmetic Mean Grouped And Ungrouped Data Formula, Japanese School Of Prague, Potassium + Oxygen = Potassium Oxide Balanced Equation, Eerie Elementary Author, Fashion Terminology With Pictures Pdf, Frisco Heritage Football Game, Things To Do In Lewistown, Pa This Weekend, Aeries Portal Excelsior,